510(k) Cybersecurity Requirements Every Maker Must Meet

Part of our FDA 2026 medical device cybersecurity submission series. For the full overview, start with FDA Cybersecurity Requirements for Medical Devices (2026).

Inadequate cybersecurity evidence can cause technical-screening questions or Additional Information requests. Device-specific, traceable documentation can help reduce avoidable review delays, but cannot guarantee a regulatory outcome.

This guide covers the governing guidance, the required document set, the testing evidence reviewers check, the postmarket plan elements that typically come in thin, the standards that anchor your artifacts, and the gap patterns that trigger deficiency letters. Work through each section before you file, not after.

Why this matters

Connected medical devices present significant patient safety and data security risks if not properly secured. Submitting inadequate cybersecurity evidence leads to costly delays, including Additional Information requests and technical-screening questions, impacting market entry and patient access to vital technologies. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explains recommendations supporting the statutory obligations in Section 524B. This guidance recommends rigorous premarket and postmarket controls. Successful submissions hinge on providing well-documented evidence that demonstrably addresses potential vulnerabilities throughout the device lifecycle. Key standards like IEC 62304 for software lifecycle processes, ISO 14971 for risk management, and the AAMI TIR97 for medical device security are foundational to aligning with regulatory requirements. Failing to meet these expectations can prevent device approval, exposing manufacturers to significant financial and reputational damage.

How 510(k), De Novo, and PMA Differ - and What That Means for Cybersecurity

The controlling document is the final guidance, "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," issued by the FDA on February 3, 2026, which implements Section 524B of the FD&C Act. It applies to all 510(k) submissions reviewed by CDRH or CBER and supersedes the June 2025 guidance, which followed the 2023 and 2014 documents. The shift is significant: Section 524B establishes specific binding obligations, while guidance recommendations remain nonbinding.

The core philosophy is a Total Product Lifecycle (TPLC) approach. Premarket documentation doesn’t stand alone; it must connect explicitly to postmarket surveillance plans, and reviewers read those two sections together. A premarket package that doesn’t anticipate lifecycle management signals incomplete security thinking. In practice, this means your postmarket monitoring plan must describe specific processes, not general intentions, because reviewers will check whether the premarket and postmarket sections tell a coherent, continuous story.

A “cyber device” includes software validated, installed, or authorized by the sponsor as a device or in a device, has the ability to connect to the internet, and contains technological characteristics that could be vulnerable to cybersecurity threats. All three criteria apply; a debug port or wireless radio alone does not establish statutory cyber-device status.

For eSTAR submissions, technical screening precedes substantive review, rather than the traditional RTA checklist. Incomplete evidence can lead to screening questions or an Additional Information request. A 510(k) applicant has 180 calendar days to provide a complete response to an AI request.

How the Three Pathways Compare on Cybersecurity

The deliverables are the same. What changes is how much justification each one carries and how closely the review team examines it.

What Section 524B Requires Across All Three Pathways

The threat model is the foundation of the entire package. Built using STRIDE methodology or an equivalent structured approach, it identifies threats, vulnerabilities, risks, assumptions, and external usage risks across the device’s attack surface. Every downstream artifact traces back to it. Traceability helps reviewers evaluate the evidence, and a threat model that doesn’t connect clearly to your risk assessment and test reports is a potential trigger for deficiency requests.

The cybersecurity risk assessment evaluates the likelihood and severity of each threat identified in the model, maps mitigations, and documents residual risk acceptance under ISO 14971. These two documents must be explicitly linked. A risk assessment should be reconciled with the threat model before submission.

Security architecture documentation should explain access controls, cryptography, trust boundaries, and security assumptions. Section 524B requires an SBOM including commercial, open-source, and off-the-shelf software components. The FDA recommends machine-readable, industry-accepted formats and component support-level and end-of-support information, but does not prescribe SPDX, CycloneDX, a format version, or VEX.

Two areas to check for evidence gaps are the unresolved anomalies assessment and cybersecurity labeling. The anomalies section documents known software defects remaining in the released device, with criteria, rationale, and a security and safety impact evaluation for each. Labeling must address cybersecurity risks, updatability, and user instructions for maintaining security configuration. These aren’t optional sections. They’re expected artifacts that reviewers check.

510(k) Cybersecurity Requirements: Security Testing Evidence

Testing documentation must demonstrate methodology, scope, results, and traceability to the threat model. A report that lists findings without connecting them back to your threat model’s identified risks creates the kind of gap that can prompt technical-screening questions or an AI request mid-review.

Static and dynamic analysis are techniques to consider within a device-specific security testing strategy, not universally mandated report types. Static analysis reviews source code for vulnerabilities during development. Dynamic analysis tests the running application for exploitable flaws under real-world conditions. Both reports must cover the testing methodology, tools used, scope of coverage, findings, and how each finding was mitigated or accepted with documented rationale. A DAST report that only covers happy-path scenarios won’t pass scrutiny for a connected device.

The FDA recommends penetration testing as part of risk-based security testing. Pen test reports must demonstrate that testers actively attempted to exploit vulnerabilities identified in the threat model, not just scan for theoretical issues. Scope must cover interfaces, protocols, and communication channels. Results must include severity ratings and remediation evidence. Every exploitable threat in the threat model should trace to either a test result confirming mitigation or a documented risk acceptance decision. Gaps in that traceability are what turn a pen test into a deficiency trigger.

Vulnerability assessments should cross-reference SBOM components against relevant vulnerability sources. The FDA does not prescribe a machine-readable vulnerability-scan report format. Submissions filed via eSTAR, mandatory for most 510(k)s since October 1, 2023, must include these reports as part of the cybersecurity section, see the FDA’s eSTAR submission template for required file formats and templates. The FDA also has authority to refuse submissions lacking cybersecurity information, which means complete, well-formatted test reports aren’t optional under any interpretation of the 510k cybersecurity requirements.

---

Ready to build submission-ready cybersecurity evidence for your pathway?

Blue Goat Cyber builds complete FDA premarket cybersecurity packages for 510(k), De Novo, and PMA submissions - threat model, SBOM, penetration testing, and eSTAR-ready documentation, engineered to withstand FDA cybersecurity review.

Book a free premarket strategy call →

---

Preparing a 510(k) cybersecurity package?

Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. → FDA premarket cybersecurity services

What a Compliant Postmarket Cybersecurity Plan Must Include

See also: Indications for Use, Predicates, and Cybersecurity Scope, Mining FDA Databases for Cyber Precedent, and Letter to File vs New 510(k).

The postmarket plan is where most internal teams run thin. It’s also the section FDA reads to assess whether your premarket security work actually continues into the device’s marketed life. A plan that describes monitoring only in generic terms will generate an AI request.

The vulnerability monitoring system must track vulnerabilities across SBOM components continuously throughout the device’s marketed life. The plan must describe how vulnerabilities are detected, assessed using clinical risk frameworks aligned with ANSI/AAMI SW96, and triaged into immediate action items versus scheduled maintenance fixes. Controlled risks and uncontrolled risks follow different decision paths, and those paths must be explicitly documented with decision criteria for each category.

Use risk-based response timelines. Section 524B calls for updates and patches on a reasonably justified regular cycle and, for critical vulnerabilities that could cause uncontrolled risks, as soon as possible out of cycle. It sets no numeric patching or customer-notification SLA. Evaluate reporting obligations under 21 CFR Parts 803 and 806 and describe secure updates and user communications.

Standards That Map to Your Submission Artifacts

Understanding which standard supports which artifact matters because it helps reviewers trace conformance and reduces the probability of receiving questions about your methodology. You don’t need to cite every standard exhaustively. You need the right standard in the right place. For a deeper walkthrough, consult our Guide to Medical Device Cybersecurity Standards (Premarket, Postmarket, & Lifecycle).

The NIST Cybersecurity Framework provides the structural backbone. Identify maps to threat modeling and the SBOM. Protect maps to access controls and encryption. Detect maps to logging and anomaly detection. Respond and Recover map to vulnerability disclosure and patching. Using NIST CSF as an organizing structure for your cybersecurity narrative makes the submission easier for reviewers to follow and demonstrates systematic coverage.

IEC 81001-5-1:2021 describes secure lifecycle processes for health software. It can support an SPDF and security evidence under the QMSR, which incorporates ISO 13485:2016. Use the current FDA recognition entry and its scope when relying on a declaration of conformity; recognition does not make use of a voluntary standard mandatory.

IEC 62443, particularly part 4-1, covers interconnected devices, supply chain security, zones, conduits, and defense-in-depth architecture. It complements IEC 81001-5-1 but doesn’t replace submission-specific requirements. ISO 27001 principles for information security management can also inform your access control and organizational security documentation, though it isn’t a substitute for device-specific standards. AAMI TIR57 is recognized for risk assessment methodology and can be cited in the risk management file to support your threat model and risk assessment approach. Citing these standards adds traceability for reviewers, but the underlying artifacts still need to exist and connect to each other.

Common Gaps That Trigger Deficiencies and How to Close Them

Most cybersecurity deficiencies share the same root cause: documentation built in silos rather than as a connected body of evidence. Closing the gaps before submission is significantly cheaper than responding to an AI hold during review.

The most frequent deficiency pattern is a disconnected documentation set. A threat model that doesn’t link to the risk assessment. A risk assessment that doesn’t map to test reports. Test reports that don’t reference the SBOM. Reviewers need a coherent narrative across all artifacts. Building traceability matrices that explicitly tie these documents together is one of the highest-value pre-submission quality checks you can run.

SBOMs missing end-of-life dates, dependency trees, or CVE cross-references generate AI requests consistently. Any component without a corresponding vulnerability assessment is a gap that reviewers will flag. If penetration test scope excludes interfaces that appear in the security architecture diagram, expect a question about why. Every component in the SBOM needs a clear line to either a test result or a documented risk acceptance, with no components left floating without coverage.

Thin postmarket plans are a reliable deficiency trigger. Generic monitoring language without documented processes for vulnerability triage, disclosure timelines, or update mechanisms won’t satisfy reviewers who are checking whether your 510(k) cybersecurity requirements coverage extends into the device’s marketed life. This is the area where most in-house teams lack bandwidth even when they have the technical knowledge. We build submission-ready cybersecurity packages at Blue Goat Cyber that address these gaps before the file reaches FDA, covering SBOM generation, threat modeling, pen test execution, and postmarket plan documentation. For device makers without dedicated cybersecurity staff, end-to-end support significantly reduces the probability of a deficiency letter and the timeline impact that comes with it; see our Medical Device Cybersecurity Best Practices for practical steps teams can take.

Build the Package Before Submission, Not After

A 510(k) cybersecurity package isn’t a collection of documents. It’s a connected body of evidence that tells a coherent security story from design through deployment. The five core elements are a traceable threat model, a complete SBOM with vulnerability linkage, rigorous testing reports tied to the threat model, a living postmarket plan with specific timelines and processes, and standards-aligned documentation that gives reviewers a clear conformance path.

Audit your current package against these 510(k) cybersecurity requirements before you submit. Start with traceability: follow the thread from your threat model through every downstream artifact and confirm nothing is left unlinked. Review your SBOM for missing end-of-life dates and components without vulnerability assessments. Then check whether your pen test scope covers every interface in your security architecture diagram, and confirm your postmarket plan specifies disclosure timelines and a documented update mechanism rather than describing them as future work. For an implementation-focused checklist on FDA documentation, see FDA cybersecurity guidance.

Deficiency responses cost more in time and money than getting the package right the first time. The FDA has made its expectations explicit through guidance, enforcement actions, and the statutory requirements of Section 524B. Close the gaps with evidence before you file.

How Blue Goat approaches 510(k) cybersecurity

Blue Goat Cyber builds 510(k) cybersecurity submissions against the FDA's Cybersecurity in Medical Devices final guidance dated February 3, 2026. Our team holds CISSP and OSCP credentials and includes ex-military red team operators, so security testing reflects how attackers actually behave, not a checklist tour. We produce the full Section 524B evidence package, including the SBOM in CycloneDX with VEX, the threat model traced to AAMI TIR57 and SW96 outputs, the pen test report sized to the device's risk tier, and the postmarket Cybersecurity Management Plan. Every artifact is mapped to its eSTAR v7.1 slot so reviewers find what they expect in the order they expect it. See our 510(k) cybersecurity submission service for scope and timelines. If the FDA raises a cybersecurity question, we answer it at no extra cost until the cybersecurity portion is closed.

If you want one team to own the whole cybersecurity package, see our full-service FDA premarket cybersecurity submission support.

To keep your SBOM and vulnerability records current after clearance, GoatWatch matches components to new CVEs and tracks VEX decisions.

Need help keeping these documents current between submissions? See our medical device security advisory.

Related reading: 510(k) Cleared but No Postmarket Cybersecurity: Are You Breaking the Law?, De Novo Cybersecurity Requirements for Novel Medical Devices, VxWorks Vulnerabilities in Medical Devices: Triage, SBOM & §524B Evidence.

FAQ

What cybersecurity documentation does FDA require in a 510(k) submission?

Core deliverables are a threat model, SBOM, security architecture documentation, and penetration testing evidence. For cyber devices under Section 524B, these are statutory requirements rather than recommendations. Traceability from threat to control to test result is what reviewers check first - gaps in that chain generate most cybersecurity deficiency letters, regardless of how thorough any individual document is.

How does the cybersecurity evidence burden differ between a 510(k) and a PMA?

A 510(k) focuses on demonstrating that software, connectivity, and control differences from the predicate don't increase cybersecurity risk. PMA requires deeper verification evidence - particularly for functions where a cyber event could affect safety or essential performance. De Novo sits between the two: you are often helping define what "good" looks like for a new device class, so the evidence package needs to be defensible on first principles, not just by comparison.

What makes a 510(k) cybersecurity submission fail FDA review?

The most common causes are an incomplete or superficial threat model, no traceability from threats to controls to test evidence, and an SBOM that isn't paired with a vulnerability monitoring plan. Generic penetration testing reports not tied to the specific device attack surface are also a reliable deficiency trigger. Reviewers are explicitly looking for a connected security narrative, not a folder of separately authored artifacts.

How long does FDA 510(k) cybersecurity preparation take?

Six to twelve weeks is typical for a connected device with an existing quality system. Timeline depends on whether threat modeling has started, SBOM availability, and penetration testing scope. Engaging a specialist before design freeze reduces both time and deficiency risk - post-hoc documentation built after V&V consistently takes longer because reviewers can tell when artifacts were reverse-engineered to fit a finished design.

Does eSTAR change what cybersecurity documentation we need to produce?

ESTAR doesn't add requirements - it changes how you package them. The interactive template structures your submission so reviewers can work through your cybersecurity evidence without digging through attachments. Teams that build eSTAR-aligned documentation from the start typically see fewer "can't find the artifact" information requests, which is one of the lowest-effort categories of deficiency to eliminate.

---